Table 3.
Long-term cost-effectiveness results (€)
| Ticagrelor | Clopidogrel | Incremental | Cost per QALY | |
|---|---|---|---|---|
| Swedish healthcare perspective | ||||
| Healthcare costs | 35 910 | 35 443 | 467 | |
| QALYs | 9.10 | 8.93 | 0.17 | €2747 (SEK26 206)* |
| UK healthcare perspective | ||||
| Healthcare costs | 15 628 | 15 084 | 545 | |
| QALYs | 8.60 | 8.44 | 0.16 | €3395 (£2920)* |
| German healthcare perspective | ||||
| Healthcare costs | 24 186 | 23 448 | 739 | |
| QALYs | 8.93 | 8.76 | 0.17 | €4419 |
| Brazilian public healthcare perspective | ||||
| Healthcare costs | 5855 | 5292 | 563 | |
| QALYs | 6.77 | 6.64 | 0.13 | €4471 (BRL10417)* |
*Cost per QALY in local currency.
The results in bold are based on the probabilistic simulation which does not provide meaningful levels of significant of this ratio statistic. See for example the original publication.7
QALY, quality-adjusted life-year.